IMAGIN MEDICAL CLOSES SECOND TRANCHE OF CONVERTIBLE NOTE OFFERING

Rhea-AI Summary

Imagin Medical (CSE: IME) (OTCQB: IMEXF) announced the closing of the second tranche of its Convertible Note offering, raising US$1,415,500. This brings the total amount raised to US$2,165,500. All securities related to this offering are subject to a statutory hold period of four months plus a day. Imagin is focused on enhancing cancer visualization during minimally invasive surgeries, particularly for bladder cancer, through its i/Blue™ Imaging System.

Positive

• Successfully raised US$1,415,500 in the second tranche of the Convertible Note offering.
• Total raised amount now stands at US$2,165,500.

Negative

• None.

Vancouver, B.C. and Boston, MA, Feb. 18, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD3) (“Imagin” or the “Company”) today announced that, further to its press releases of October 22 and November 10, 2020, it has closed the second tranche in the amount of US$1,415,500 of the Convertible Note offering. Total Convertible Note amount of $2,165,500 raised to date.

All securities issued in connection with the Offering will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall it constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful. These securities have not been, and will not be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States or to U.S. persons unless registered or exempt therefrom.

About Imagin Medical
Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The Company believes its first product, the i/Blue™ Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal, helping to reduce recurrence rates. The Company’s initial focus is bladder cancer. Learn more at www.imaginmedical.com.

Forward-Looking Statements
Information set forth in this news release contains forward-looking statements. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward- looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Specifically, there is no assurance the Company’s imaging system will work in the manner expected. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information. The CSE has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.

Contact:

Jim Hutchens, President & CEO Telephone: 833-246-2446

Corporate Communications:
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

FAQ

What was the purpose of Imagin Medical's recent press release dated February 18, 2021?

The press release announced the closing of the second tranche of its Convertible Note offering, raising an additional US$1,415,500.

How much has Imagin Medical raised in total from its Convertible Note offering?

Imagin Medical has raised a total of US$2,165,500 to date from its Convertible Note offering.

What is the statutory hold period for the securities issued by Imagin Medical?

The securities issued are subject to a statutory hold period of four months plus one day from the date of issuance.

What is Imagin Medical's focus in medical technology?

Imagin Medical focuses on advancing cancer visualization methods during minimally invasive surgeries, with an initial emphasis on bladder cancer.

What is the significance of the i/Blue™ Imaging System developed by Imagin Medical?

The i/Blue™ Imaging System aims to improve the efficiency and accuracy of cancer detection during surgeries, potentially reducing recurrence rates.